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Abstract: Type 2 diabetes remains an escalating problem worldwide, despite a range of 
 treatments being available. The revelation that insulin secretion is under the control of a gut hor-
mone, glucagon-like peptide 1, has led to a new paradigm in the management of type 2  diabetes, 
ie, use of medicines that directly stimulate or prolong the actions of endogenous glucagon-like 
peptide 1 at its receptors. Exenatide is an agonist at the glucagon-like peptide 1 receptor, and 
was initially developed as a subcutaneous medication twice daily (ExBID). Clinical trials 
with ExBID established a role for exenatide in the treatment of type 2 diabetes. Subsequently, 
exenatide once weekly (ExQW) was shown to have advantages over ExBID, and there is now 
more emphasis on the development of ExQW. ExQW alone reduces glycosylated hemoglobin 
(HbA
1c
) and body weight, and is well tolerated. ExQW has been compared with sitagliptin, 
pioglitazone, and metformin, and been shown to have a greater ability to reduce HbA
1c
 than 
these other medicines. The only preparation of insulin with which ExQW has been compared is 
insulin glargine, and ExQW had some favorable properties in this comparison, notably causing 
weight loss compared with the weight gain on insulin glargine. ExQW has been compared with 
another glucagon-like peptide 1 receptor agonist, liraglutide, and was noninferior to liraglutide 
in reducing HbA
1c
. The small amount of evidence available shows that subjects with type 2 
diabetes prefer ExQW to ExBID, and that adherence is high in the clinical trial setting. Health 
care and economic modeling suggests that ExQW will reduce diabetic complications and be 
cost-effective, compared with other medications, in long-term use. Little is known about whether 
subjects with type 2 diabetes prefer ExQW to other medicines, and whether adherence is good 
with ExQW in practice. These important topics require further study.
Keywords: exenatide, twice daily, once weekly, insulin, metformin, sitagliptin, type 2 
diabetes
Introduction
The prevalence of diabetes in the US is about 8% (24 million people), and 90% is type 2 
diabetes, which has both lifestyle and genetic components.1 Despite the treatments 
available for type 2 diabetes, about two thirds of subjects die from heart disease or 
stroke. Diabetes is also a leading cause of blindness, end-stage kidney failure, and lower 
limb amputations.1 Clearly, there is a need for good treatments for type 2 diabetes.
Medications are used in subjects with type 2 diabetes, when lifestyle changes have 
failed to manage their condition. Metformin is the medication of first choice in subjects 
with the disease. When lifestyle changes and the highest tolerated dose of metformin 
fail to provide control, a sulfonylurea is often added. The glitazones are an option as 
dual or additional therapy with metformin and/or a sulfonylurea. Finally, when oral 
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medications do not control the disease, injectable insulin 
is added. Despite these medicines, type 2 diabetes is often 
progressive, with subjects unable to maintain long-term 
glycemic control.2 Also, some of these diabetic medicines 
(notably insulin and the sulfonylureas) increase body weight, 
which contributes further to diabetes.
Some recent physiological discoveries have opened 
up a new paradigm in the treatment of diabetes. In type 2 
diabetes, hyperglycemia is due to a relative lack of insulin 
production and reduction in insulin sensitivity.1 Classically, 
glucose levels in the pancreatic cells, which relate to blood 
glucose levels, were considered to be the main controller 
of insulin levels. Recently, it has been discovered that gut 
peptides influence insulin secretion, and these peptides and 
their receptors are the target for a range of new drugs being 
introduced into the treatment of type 2 diabetes.
Glucagon-like peptide 1 (GLP-1) and gastric inhibitory 
peptide are released in response to a meal, and have already 
been reviewed in detail.3 Both of these gut hormones augment 
glucose-mediated insulin secretion, but only GLP-1 sup-
presses glucagon secretion, inhibits gastric emptying, and 
reduces appetite.3 Both GLP-1 and gastric inhibitory peptide 
are rapidly broken down by dipeptidyl peptidase-4, and thus 
have only short half-lives and biological effects.3 Production 
of both GLP-1 and gastric inhibitory peptide are severely 
reduced in subjects with type 2 diabetes.3 Levels of GLP-1 
and gastric inhibitory peptide can be increased by inhibiting 
dipeptidyl peptidase-4, and this in turn will increase glucose-
mediated insulin secretion.3 The major difference between 
the sulfonylureas and drugs that increase the stimulation of 
the GLP-1 receptors is that the sulfonylureas increase insulin 
release independently of glucose, whereas stimulation of the 
GLP-1 receptor only augments glucose-mediated insulin 
secretion.
Exendin-4 is a 39-amino acid peptide, which acts as an 
agonist at GLP-1 receptors and is resistant to breakdown, 
as described previously.4 Synthetic exendin-4 (exenatide) 
is used to stimulate the GLP-1 receptor in type 2 diabetes.4 
Exenatide augments glucose-mediated insulin secretion and 
inhibits glucagon secretion, and this decreases glycosylated 
hemoglobin (HbA
1c
) and fasting plasma glucose levels.4 
Exenatide also inhibits gastric emptying, and reduces appetite 
and food intake.4 Exenatide was initially used twice a day 
subcutaneously (ExBID) immediately before breakfast and 
dinner, but has recently been developed for once a week use 
(ExQW), and the subcutaneous injection does not need to 
be before a meal. Recently, several clinical trials and health 
care and economic modeling studies involving ExQW have 
been published, but there have been no reviews as yet that 
specifically relate to ExQW.
Initially, in this review, there is a brief outline of the clini-
cal trials with ExBID, which established a role for exenatide 
in the treatment of type 2 diabetes. Subsequently, ExQW was 
shown to have advantages over ExBID, and there is now more 
emphasis on the development of ExQW. The comparison 
of ExQW with other antidiabetic drugs is discussed further 
on, and ExQW is shown to have some favorable properties 
compared with the other antidiabetic drugs. In describing 
clinical trials, only statistically significant differences are 
considered important, and when there is no significant differ-
ence, values are considered to be similar. ExQW is delivered 
subcutaneously, which contributes to patient preference, 
and this important issue is also discussed. To date, there 
are no clinical trials reporting clinical outcomes for ExQW, 
but the health care and economic considerations have been 
modeled, and this modeling is discussed. Finally, there is a 
commentary on the present findings, and the need for future 
research with ExQW.
Exenatide twice daily
ExBID has been shown to reduce HbA
1c
 and cause weight 
loss when used alone versus placebo, including in subjects 
with type 2 diabetes being treated with metformin, a sulfony-
lurea, or the combination of metformin and a sulfonylurea.4 
ExBID has also been shown to decrease HbA
1c
 and body 
weight in subjects with type 2 diabetes being treated with 
a thiazolidinedione (pioglitazone or rosiglitazone) in the 
presence or absence of metformin.5 Recently, this has been 
extended to include in the presence of insulin. Thus, ExBID 
has been shown to reduce HbA
1c
 and body weight in sub-
jects with poorly controlled type 2 diabetes, despite taking 
insulin glargine alone or in combination with metformin or 
pioglitazone (or both agents).6
Importantly, ExBID has been compared with the stan-
dard treatments for type 2 diabetes and shown to have some 
favorable effects. Two studies of subjects with inadequately 
controlled type 2 diabetes, despite using metformin and/or 
sulfonylurea therapy, randomized their subjects to either 
ExBID or insulin glargine, and showed that the reduction 
in HbA 
1c
 was the same in both groups, but ExBID caused 
a reduction in body weight, whereas subjects taking insulin 
had an increase in body weight. However, ExBID caused 
more adverse gastrointestinal effects than insulin glargine 
in both studies.7,8 In another study, ExBID was compared 
with premixed insulin aspart in subjects with type 2 diabetes 
being treated with metformin, and shown to be noninferior 
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to insulin in reducing HbA
1c
. Again, ExBID was shown to 
reduce body weight, whereas there was an increase with 
insulin aspart.9
When ExBID was compared with a sulfonylurea, gliben-
clamide, in subjects with uncontrolled type 2 diabetes despite 
receiving treatment with metformin, ExBID and glibencl-
amide decreased HbA
1c
 to a similar extent. With ExBID the 
subjects lost weight, whereas with glibenclamide they gained 
weight. Fasting insulin levels and insulin resistance were 
reduced by ExBID, but not by glibenclamide.10 A comparison 
of ExBID and another sulfonylurea  (glimepiride) also showed 
that both agents caused a similar decrease in HbA
1c
, but 
ExBID was associated with body weight loss and reduced 
insulin resistance, whereas glimepiride did not have these 
effects.11
An important finding regarding ExBID has come from 
a retrospective database analysis showing that it reduces 
the risk of cardiovascular events and hospitalizations. The 
data used were from the LifeLink database of medical and 
insurance claims. Subjects with type 2 diabetes but no his-
tory of cardiovascular events were assigned to an ExBID 
or non-exenatide cohort on their first new prescription 
filled. The cohorts were not matched at the start, because 
the 39,275 patients treated with ExBID were more likely 
to have ischemic heart disease, obesity, hyperlipidemia, 
hypertension, and/or other comorbidities at baseline than the 
381,218 patients in the non-exenatide cohort. Nevertheless, 
going forward, the ExBID cohort had a smaller risk of 
cardiovascular disease events or hospitalizations than the 
non-exenatide group.12
ExBID has been associated with an increased incidence 
of acute pancreatitis during post-marketing surveillance. 
However, a retrospective cohort study of 786,656 subjects 
has shown an increased incidence of pancreatitis in diabetic 
versus nondiabetic subjects. The same study showed no asso-
ciation between ExBID and acute pancreatitis.13 Two other 
recent studies have confirmed that there is no relationship 
between ExBID and acute pancreatitis.14,15
Efficacy, safety, and tolerability  
of ExQW versus ExBID
ExQw alone
The long-acting formulation of exenatide contains ExBID 
encapsulated in 0.06 mm diameter microspheres of medical 
grade poly-(D,L-lactide-co-glycolide). After mechanical 
suspension and subcutaneous injection, the microspheres 
hydrate in situ and adhere to one another to form an amalgam. 
Only the loosely bound surface exenatide (1%) releases in 
the first few hours, whereas exenatide lodged in the deeper 
interstices diffuses out slowly, with a time to maximum 
concentration of about 2 weeks. Finally, fully encapsulated 
exenatide, which is inaccessible to diffusion, releases over 
a longer period, with a time to maximum of about 7 weeks, 
as already reviewed.16
In 62 subjects with type 2 diabetes, a single subcutaneous 
dose of ExQW at 2.5, 5, 7 or 10 mg gave three peak plasma 
concentrations after about 3.5 hours, and 2 and 6 weeks, 
which represents the three phases of drug release from the 
microspheres. In 45 subjects with type 2 diabetes on weekly 
injections of ExQW at 0.8 and 2 mg, it was 2 weeks before 
ExQW 2 mg reached the minimum effective concentration, 
which remained in the target therapeutic range until the 
injections were stopped. At the lower dose of ExQW, it took 
longer to reach the minimum effective concentration. Both 
doses of ExQW decreased HbA
1c
 and fasting plasma glucose, 
but only the higher dose of the ExQW (2 mg) reduced body 
weight. Nausea, which was mild, was observed in about one 
quarter of the subjects taking ExQW compared with 12% in 
those on placebo. Although hypoglycemia was observed in 
25% of subjects with type 2 diabetes on ExQW, none of it 
was severe.17
ExQW 2 mg was tested in 43 subjects with type 2 diabetes 
and shown to be beneficial in comparison with placebo. The 
enrolled subjects had a mean HbA
1c
 of 8.5% and a fasting 
blood glucose of 9.9 mmol/L, and most (n = 27) were receiv-
ing metformin. The subjects were randomized to placebo 
or ExQW at 0.8 or 2 mg weekly, and those on the 2 mg 
dose reached a therapeutic concentration (50 pg/mL) within 
2 weeks and retained it for 15 weeks, whereas those on the 
0.8 mg only reached a borderline therapeutic concentration. 
When the ExQW was stopped after week 15, it was 3 weeks 
before the plasma concentrations became too low to be 
therapeutic. After 15 weeks, HbA
1c
 was reduced by 1.8% 
and 2.1% on ExQW 0.8 and 2 mg, respectively, and fasting 
plasma glucose was reduced by about 2.4 mmol/L on each 
dose strength. The lower dose of exenatide had no effect on 
body weight whereas exenatide 2 mg caused a weight loss 
of 3.8 kg. The most common adverse effect was nausea, 
followed by gastroenteritis and bruising at the injection 
site. There was no major hypoglycemia with ExQW over 
15 weeks.18
In 29 Japanese subjects with type 2 diabetes suboptimally 
controlled on metformin, a sulfonylurea, a thiazolidinedione, 
or a combination of these, exenatide 0.8 mg and 2 mg once 
weekly gave steady-state concentrations by week 8. At 
10 weeks, exenatide 0.8 and 2 mg once weekly had reduced 
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HbA
1c
 by 0.6% and 1.1%, respectively. Only 2 mg of 
exenatide had a definite ability to reduce fasting and post-
prandial glucose. The most common side effect was mild to 
moderate hardening/thickening of the skin at the injection 
site followed by mild nausea, and no serious hypoglycemia 
was observed. Treatment-emergent antibodies to exenatide 
were present in about two thirds of treated subjects, but did 
not affect changes in HbA
1c
.19
ExQw compared with ExBiD
ExBID and ExQW have been compared in the DURATION-1 
(Diabetes Therapy Utilization: Changes in A
1c
, Weight, 
and Other Factors Through Intervention with Exenatide 
Once Weekly) study, and the once-weekly formulation was 
shown to be at least as good as the twice-daily formulation. 
DURATION-1 was an open-label, noninferiority compari-
son between ExBID and ExQW. The DURATION-1 study 
enrolled 295 subjects with type 2 diabetes, a mean age of 
55 years, a baseline HbA
1c
 of 8.3%, and fasting plasma glu-
cose of about 8.4 mmol/L, who were being managed by diet 
and exercise (approximately 15%), metformin alone (about 
36%), or in combination with other drugs (about 38%), or 
other antidiabetic drugs. Subjects were randomized, and 
then underwent a 3-day lead-in period of exenatide 5 µg 
twice daily, before receiving exenatide 2 mg once a week 
or exenatide 5 µg twice daily for 28 days followed by 10 µg 
twice daily for 30 weeks. It only took 2 weeks to obtain 
the therapeutic range of exenatide with the once-weekly 
 preparation. The two preparations had similar effects on HbA
1c
 
over 9 weeks, beyond which ExQW caused a greater reduc-
tion in HbA
1c
 (1.9% at 30 weeks versus 1.5% with ExBID). 
ExQW also caused a greater reduction in fasting plasma 
glucose (2.3 mmol/L) than ExBID (1.4 mmol/L), whereas 
ExBID caused a greater reduction in postprandial glucose 
(6.9 mmol/L) than ExQW (5.3 mol/L). Both preparations of 
exenatide caused a similar decrease in low-density lipoprotein 
cholesterol, triglycerides, systolic and diastolic blood pres-
sure, and body weight (about 3.65 kg). Nausea was more 
common with ExBID than with ExQW (35% versus 26%), 
as was vomiting (19% versus 11%), upper respiratory tract 
infection (17% versus 8%), and bruising at the injection site 
(10% versus 5%). The incidence of diarrhea, constipation, and 
urinary tract infection was similar with both preparations, but 
pruritus at the injection site was more common with ExQW 
(18%) than with ExBID (1%).20
DURATION-1 has been followed up at 52 weeks, with 
subjects taking ExQW continuing on this therapy, and the 
subjects with type 2 diabetes taking ExBID being switched 
to ExQW 2 mg. In the subjects continuing with ExQW, the 
reduction in HbA
1c
 was maintained at 52 weeks, whereas 
those who switched to ExQW had an improvement in HbA
1c
. 
Subjects on ExBID who were switched to ExQW had a 
transient increase in fasting blood glucose, followed by a 
decrease after 2 weeks, and this increase was probably due to 
short-term subtherapeutic levels of exenatide. By 52 weeks, 
the reduction in diastolic and systolic blood pressure on both 
exenatide protocols had reached clinical significance, with 
decreases of 6.2/2.8 mmHg in those continuing on ExQW. 
The switch to ExQW was associated with an increase in 
pruritus at the injection site. There were no episodes of major 
hypoglycemia, and only minor hypoglycemia occurred in 
subjects taking sulfonylureas.21
A further follow-up of DURATION-1 out to 2 years 
showed that ExQW continued to be well tolerated. Follow-up 
also demonstrated sustained glucose control, weight loss, and 
blood pressure reductions. There were also small decreases 
in cholesterol, low-density lipoprotein cholesterol, and 
triglycerides.22
DURATION-5 was similar in design to DURATION-1, 
and had similar findings. DURATION-5 enrolled 252 sub-
jects with type 2 diabetes and an HbA
1c
 of 8.4%, and the 
reduction in HbA
1c
 after 24 weeks was greater with ExQW 
(1.6%) than with ExBID (0.9%). Weight loss was similar in 
both groups. Heart rate increased by 4.1 and 2.1 beats per 
minute with ExQW and ExBID, respectively. Nausea was 
less common with ExQW than with ExBID (14% versus 
35%), as was vomiting (5% versus 9%), but erythema at 
the injection site was more common with ExQW than with 
ExBID (5.4% versus 2.4%).23
The results from DURATION-1 and DURATION-5 have 
been combined for analysis of safety and tolerability. Nausea 
was less common with ExQW (20.9%) than with ExBID 
(35.7%), as was vomiting (7.9% versus 14.2%, respectively), 
and both of these adverse effects decreased in incidence with 
time. Erythema and pruritus at the injection site were more 
common with ExQW than ExBID (erythema, 6.5% versus 
1.1%; pruritus, 11.9% versus 1.1%), and these adverse effects 
also decreased over time. No subjects had major hypogly-
cemia, but subjects in both groups using sulfonylureas did 
have some minor hypoglycemia.24
Subpopulation analysis of the data with ExQW has been 
undertaken by Amylin Pharmaceuticals (San Diego, CA), 
the company developing ExQW. This analysis included 
data from DURATION 1–6, and another trial that has not 
been published as yet in a peer- reviewed journal. ExQW 
reduced HbA
1c
 levels, fasting  glucose, and body weight in 
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all  subpopulations (, or $65 years, gender, race, duration 
of diabetes, and body mass index). Low-density lipoprotein, 
cholesterol, and blood pressure was reduced in all subpopula-
tions except Blacks. Hypoglycemia was uncommon (2.3%) 
except in subjects who were also taking sulfonylureas.25
Comparative clinical trials of ExQW 
and other antidiabetic drugs
Comparison with sitagliptin, pioglitazone, 
and metformin
ExQW has been compared with sitagliptin, pioglitazone, and 
metformin and shown to have a favorable profile compared 
with each of these agents. In DURATION-2, ExQW was com-
pared with sitagliptin or pioglitazone in subjects with type 2 
diabetes taking metformin in a double-blind, double-dummy 
clinical trial. The 491 enrolled subjects had a mean age of 
52 years and an HbA
1c
 of about 8.5%, and were randomized 
to ExQW 2 mg, sitagliptin 100 mg, or pioglitazone 45 mg 
for 26 weeks. The HbA
1c
 levels were lowered to 7.2% with 
ExQW, which was significantly greater than the 7.7% with 
sitagliptin or 7.4% with pioglitazone. Fasting blood glucose 
was lowered by 1.8 mmol/L with ExQW, which was similar 
to that with pioglitazone (1.5 mmol/L) but greater than with 
sitagliptin (0.9 mmol/L). Subjects taking ExQW lost 2.3 kg, 
which was greater than the loss with sitagliptin (0.8 kg), 
whereas subjects taking pioglitazone gained 2.8 kg. ExQW 
caused a reduction in systolic blood pressure (4 mmHg), 
whereas sitagliptin and pioglitazone had little effect on blood 
pressure after 16 weeks.26
There was no major hypoglycemia with ExQW, sitaglip-
tin, or pioglitazone in DURATION-2. Minor hypoglycemia 
occurred in 1% of subjects with type 2 diabetes taking ExQW, 
3% of those on sitagliptin, and 1% of those on pioglitazone. 
The most common adverse effects were nausea and diarrhea 
with ExQW and sitagliptin. With pioglitazone, the most com-
mon adverse effects were upper respiratory tract infection 
and peripheral oedema.26
Subsequently, all subjects with type 2 diabetes in 
DURATION-2 received ExQW. After 26 weeks, the subjects 
who changed from sitagliptin to ExQW had reduced HbA
1c
, 
fasting plasma glucose, and weight, whereas subjects who 
were changed from pioglitazone to ExQW has no change in 
HbA
1c
 or fasting blood glucose, but did lose weight.27
The DURATION-4 trial compared ExQW with met-
formin 2 g/day, sitagliptin 100 mg/day, or pioglitazone 
45 mg/day in 822 subjects with type 2 diabetes who were 
diabetes drug-naïve. After 26 weeks, HbA
1c
 was decreased by 
1.5% by ExQW, 1.5% by metformin, 1.6% by pioglitazone, 
and 1.2% by sitagliptin. Body weight decreased with ExQW, 
metformin, and sitagliptin, but increased with pioglitazone. 
Nausea and injection site reactions were only observed with 
ExQW. There were no incidents of major hypoglycemia.28
Comparison with insulin
The only preparation of insulin which ExQW has been 
compared with in a peer-reviewed journal is insulin 
glargine, and ExQW showed some favorable properties in 
this comparison. In DURATION-3, ExQW was compared 
with insulin glargine in subjects with type 2 diabetes. In 
this open-label, randomized, parallel-group Phase III study, 
456 subjects with suboptimal glycemic control despite 
maximum tolerated doses of metformin or a combination of 
metformin and sulfonylureas were randomized to ExQW or 
insulin glargine. Subjects started insulin glargine 10 IU/day, 
measured their fasting blood glucose concentrations every 
morning, and adjusted insulin doses to achieve a plasma 
glucose of 4.0–5.5 mmol/L. After 26 weeks, the reduction 
in HbA
1c
 from a baseline of 8.3% was 1.5% with ExQW, 
which was significantly greater than the 1.3% with insulin 
glargine. There was a larger reduction in fasting blood glu-
cose with insulin glargine (2.8 mmol/L) than with ExQW 
(2.1 mmol/L), but a bigger reduction in postprandial glucose 
with ExQW than insulin glargine. Body weight decreased 
by 2.6 kg with ExQW, but increased by 1.4 kg with insulin 
glargine. ExQW reduced blood pressure by 4.2/1.5 mmHg 
and increased heart rate by 1.97 beats per minute, whereas 
insulin glargine only reduced systolic blood pressure and had 
no effect on heart rate.29
In DURATION-3, minor hypoglycemia was observed 
in fewer subjects receiving ExQW (8%) than those on 
insulin glargine (26%), as was the occurrence of symp-
toms of  hypoglycemia (13% versus 31%). Gastrointestinal 
side effects were more common with ExQW than insulin 
glargine, whereas nasopharyngitis and headache were 
more common with insulin than exenatide. One subject 
taking ExQW had edematous pancreatitis but made a full 
recovery.29
ExQW has also been compared with insulin glargine 
in 427 Japanese subjects with type 2 diabetes and already 
taking oral drugs for treatment of diabetes. After 26 weeks, 
HbA
1c
 was reduced by 1.1% and 0.7% in the ExQW and 
insulin groups, respectively. Body weight was decreased by 
ExQW but increased slightly with insulin glargine. ExQW 
decreased low-density lipoprotein cholesterol, whereas 
insulin did not. ExQW had a lower risk of hypoglycemia 
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than insulin glargine, but a higher risk of adverse effects at 
the injection site.30
Comparison with liraglutide
ExQW was compared with liraglutide in DURATION-6. 
Liraglutide is also an agonist at the GLP-1 receptor, and is 
used subcutaneously at 1.8 mg once a day in the treatment 
of type 2 diabetes. DURATION-6 enrolled 911 subjects 
with type 2 diabetes, which was poorly controlled despite 
the use of metformin, a sulfonylurea, or metformin and a 
sulfonylurea or pioglitazone. In the first four weeks of the 
trial, 15 subjects in the liraglutide group withdrew because of 
adverse gastrointestinal effects, whereas none in the ExQW 
withdrew for this reason. At baseline, HbA
1c
 was about 
8.4%, and after 26 weeks was reduced by 1.3% on ExQW 
and 1.5% on liraglutide. Although the effect on HbA
1c
 was 
greater with liraglutide than with ExQW, statistical analysis 
showed that ExQW was noninferior to liraglutide. Weight 
loss was greater with liraglutide than with ExQW (about 
3.5 kg versus 2.8 kg at 26 weeks). Adverse gastrointestinal 
effects remained more common with liraglutide than with 
ExQW (nausea, 21% versus 9%; vomiting, 11% versus 
4%; diarrhea, 13% versus 6%), whereas injection site 
nodules were more common with ExQW than with lira-
glutide (3% versus ,1%). No major hypoglycemia was 
observed with either drug, but minor hypoglycemia in the 
absence of a sulfonylurea was observed in 3% of subjects 
taking liraglutide and 4% taking ExQW. In subjects taking 
 sulfonylureas, the rate of minor hypoglycemia was 12% 
with liraglutide and 15% with ExQW.31
A meta-analysis that combined all the information for 
ExQW and liraglutide showed that HbA 
1c
 was lowered by 
1.15% on ExQW, 1.01% on liraglutide 1.2 mg, and 1.18% 
on liraglutide 1.8 mg, and concluded that there were no 
meaningful differences in HbA
1c
-lowering with ExQW and 
the two doses of liraglutide.32
Patient preference and adherence
In DURATION-1, treatment adherence (measured as injections 
received/injections planned) was 98% for both ExBID and 
ExQW over 30 weeks.19 During DURATION-1 and its exten-
sion to 52 weeks, treatment satisfaction was assessed using 
the Diabetes Treatment Satisfaction Questionnaire (DTSQ).33 
The DTSQ assesses six items, ie, “current treatment”, 
 “convenience”, “flexibility”, “understanding”,  “recommend”, 
and “continue”, and uses a Likert scale of 0–7 for each 
item. After 30 weeks of ExQW, there were improvements 
for all items except for perceived hypoglycemic frequency. 
After 30 weeks, subjects taking ExBID were switched to 
ExQW, and this improved the DTSQ score. The Impact of 
Weight on Quality of Life Questionnaire-Lite (IWQOL),34 
which has domains on “physical function”, “self-esteem”, 
“sex life”, “public distress”, and “work” was improved by 
both ExQW and ExBID. Furthermore, when subjects switched 
from ExBID to ExQW, there was a further improvement 
in quality of life. Nausea with exenatide did not alter the 
improvements in DTSQ score or IWQOL.35
In DURATION-2, ExQW was more effective than sita-
gliptin or pioglitazone in reducing HbA
1c
, and also reduced 
body weight.26 After 26 weeks, the DTSQ score was improved 
by ExQW, sitagliptin, and pioglitazone in DURATION-2. 
However, the improvement was greater with ExQW than with 
sitagliptin. IWQOL was improved by ExQW and sitagliptin, 
but not by pioglitazone, which increased body weight. The 
Psychological General Well-Being (PGWB) index has six 
dimensions, ie, anxiety, depressed mood, positive well-being, 
self-control, general health, and vitality.36 ExQW, sitagliptin, 
and pioglitazone all improved the PGWB.26,37
There is very little information about adherence with 
exenatide. In DURATION-1, adherence with ExQW and 
ExBID was very high at 98% for both formulations over 
30 weeks.20 A retrospective cohort analysis of adher-
ence with ExBID or insulin glargine used the HealthCore 
 Integrated Research Database™, and calculated adherence 
as the 12-month medication ratio, ie, the aggregate days of 
supply of all fills for therapy observed over 12 months after 
initiation divided by 365 days. Adherence was 68% with 
ExBID, which was significantly higher than the 58% for 
insulin glargine.38
Health care and economic 
considerations
Center for Outcomes Research model
The Center for Outcomes Research (CORE) has developed 
a diabetes model which determines the long-term health out-
comes and economic consequences of implementing different 
treatment strategies. The model takes account of baseline 
cohort characteristics, any past history of complications, 
current and future diabetes management, and concomitant 
medications. From this model, development of complica-
tions, life expectancy, quality-adjusted life expectancy, and 
total costs within populations can be calculated.39
In subjects with poorly controlled diabetes, despite use 
of metformin and/or sulfonylureas, Phase III clinical trials 
have shown that ExBID reduced HbA
1c
,40–42 and these data 
have been used in the CORE diabetes model to determine 
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the effect of adding ExBID versus not adding ExBID. This 
modeling showed that the increased cost over 30 years with 
ExBID was associated with increased life expectancy and 
increased quality-adjusted life expectancy.43
CORE has also been applied to DURATION-2, in which 
ExQW was compared with sitagliptin or pioglitazone in 
subjects with poorly controlled diabetes, despite taking met-
formin, and it was shown that subjects on ExQW achieved 
a bigger reduction in HbA
1c
 than those on sitagliptin or 
pioglitazone.26 In this model, use of ExQW was extended 
beyond the 6 months of DURATION-2, with a deterioration 
of glycemic control until the subjects were switched to basal 
insulin after 3 years. After 35 years, in the CORE model-
ing of DURATION-2, ExQW increased life expectancy by 
0.28 and 0.17 years, and quality-adjusted life years by 0.28 
and 0.24 years, compared with sitagliptin and pioglitazone, 
respectively. The risk of 14 of 16 diabetic complications 
(eg, myocardial infarction, renal disease, eye disease, ulcer, 
neuropathy) was lower with ExQW than with sitagliptin, 
but for two other complications, ie, first stroke and heart 
failure, the risk was slightly higher with ExQW than with 
sitagliptin. The relative risk of 13 of 16 complications was 
also lower with ExQW than with pioglitazone, but the risk of 
acute myocardial infarction, stroke, and angina was slightly 
higher with ExQW than with pioglitazone. ExQW had lower 
complication costs of US$2215 and US$933 versus sitaglip-
tin and pioglitazone, respectively. The biggest limitation in 
this study is that a relative short clinical trial of 6 months 
with surrogate endpoints only had been used in the model-
ing over 35 years.44
The CORE model has also been applied to  DURATION-3, 
the trial showing that subjects with suboptimally man-
aged diabetes despite taking metformin alone or with 
sulfonylureas had a bigger reduction in HbA
1c
 with ExQW 
than with insulin glargine 10 IU/day, and weight loss was 
observed with ExQW, whereas insulin glargine increased 
body weight.29 From the CORE diabetes model, life expec-
tancy and quality-adjusted life expectancy were higher 
with ExQW than with insulin glargine, and there was also 
an increased time to diabetic complications with ExQW 
compared with insulin glargine. At the time of the analysis, 
the cost of ExQW was unknown, but if it was the same as 
liraglutide 1. 8 mg, the ExQW would be more costly than 
insulin glargine. However, it should be noted that this was 
partly due to the increased life expectancy with ExQW, and 
thus may be acceptable.45
Another group applied the CORE diabetes model to 
DURATION-3, with the known price of ExQW in the US, 
and came up with similar results. Compared with insulin 
glargine, ExQW over 35 years would reduce the risk of 
cardiovascular disease (except stroke), renal disease, eye 
disease, and ulcer/neuropathy. ExQW would increase life 
expectancy and quality-adjusted life expectancy, and this 
would lead to increased costs with ExQW compared with 
insulin glargine of US$15,936 per quality-adjusted life year, 
which is under the acceptable rate for a quality-adjusted life 
year of US$50,000.46
The LEAD-6 (Liraglutide Once Daily Compared With 
Exenatide Twice Daily) trial comparing liraglutide with 
ExBID was also subjected to the CORE diabetes model, 
which showed that liraglutide improved quality of life and 
reduced the incidence of diabetes-related complications 
compared with ExBID. Liraglutide was cost-effective from 
a health care perspective in Switzerland, Denmark, Norway, 
The Netherlands, and Austria.47 As noted in the previous 
section, ExQW is more effective than ExBID at lowering 
HbA
1c
 and fasting glucose, and is more convenient to use 
than ExBID. Thus, a more appropriate comparison would 
be liraglutide and ExQW.
The Archimedes model
Another model/simulation has been used to predict car-
diovascular outcomes with a once-weekly GLP-1 receptor 
agonist such as ExQW in subjects with type 2 diabetes. The 
Archimedes model is a clinically detailed simulation model 
of human physiology, disease progression, and health care 
delivery which was initially developed as a diabetes model.48 
The Archimedes diabetes model was then validated against 
more than 50 major clinical trials, including some in subjects 
with diabetes.49
For the Archimedes diabetes modeling of the effect 
of GLP-1 agonists, the population used in the simulation 
study were derived from the National Health and Nutrition 
Examination Survey (NHANES). In the NHANES virtual 
population with type 2 diabetes, the HbA
1c
 level is 8.1% 
despite use of metformin with or without a sulfonylurea.50 
Four populations were simulated, ie, standard care, intensive 
glycemic control, glycemic control and weight reduction, and 
one with additional improvements in systolic blood pressure 
and lipids, with these last two simulations representing the 
effects of GLP-1 receptor agonist. In this model, the GLP-1 
receptor agonist achieved a decrease in HbA
1c
 over the first 
year, with some upward drift over time. By year 20, intensive 
glycemic control led to a 6.1% reduction in macrovascular 
events relative to standard care, and this represented a reduc-
tion in fatal and nonfatal myocardial infarction, stroke, and 
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death from coronary artery disease of 9.2%, 2.2%, and 10.2%, 
 respectively. With glycemic control and weight reduction, 
the rates of myocardial infarction, stroke, and coronary death 
were increased to 19.5%, 6.2%, and 17.6%, respectively. With 
the addition of reduced blood pressure and lipid controls, the 
reductions in myocardial infarction, stroke, and coronary 
death were 26.7%, 10.7%, and 24.8%, respectively. Only the 
GLP-1 receptor agonist simulations led to a reduction in the 
early signs of renal disease (macroalbuminuria).51
The Archimedes model and the NHANES population 
have also been used to compare ExQW with insulin and pio-
glitazone in subjects with type 2 diabetes taking metformin. 
The model included both moderate and high adherence with 
insulin. Data from four of the DURATION trials (1, 2, 3, 
and 5) were used to quantify the effects of ExQW. With this 
model, after one year, HbA
1c
 decreased by about 1.5% with 
ExQW, which was more than the 1% with pioglitazone and 
high adherence with insulin and the 0.5% with moderate 
adherence with insulin. Body weight decreased with ExQW, 
but increased with insulin and pioglitazone. After 20 years, 
major adverse cardiovascular events were lower in this simu-
lation with ExQW than with high or moderate adherence to 
insulin or pioglitazone. At 5 years, there were increased life 
years and quality-adjusted life years with ExQW, compared 
with insulin and pioglitazone, and this continued up to the 
20-year mark. A limitation of this study was that subjects 
with type 2 diabetes were assumed to be 100% adherent with 
ExQW, with high adherence to insulin and pioglitazone, 
which is not realistic.52
Commentary
Long-term studies of clinical endpoints 
and safety with ExQw
The trials of ExQW discussed in this review have described 
the effects on surrogate endpoints (eg, HbA
1c
) for type 2 
 diabetes. The much more important endpoints are clinical 
ones, such as myocardial infarction and hospitalization. 
Recently, a retrospective cohort trial has suggested that 
ExBID is associated with a lower risk of cardiovascular 
disease events and hospitalizations than treatment with other 
glucose-lowering therapies,12 but such information is not 
available from a prospective trial or for ExQW. The model-
ing studies suggest that ExQW will reduce cardiovascular 
endpoints, but it is important that clinical trials or evaluations 
are undertaken to determine whether ExQW does lower the 
incidence of cardiovascular disease and hospitalizations.
Based on postmarketing data, ExBID was associated with 
acute pancreatitis, including fatal and nonfatal  hemorrhagic 
or necrotizing pancreatitis.53 Although recent evidence 
 suggests that ExBID is not linked with pancreatitis, as 
discussed earlier, it does raise the issue of long-term safety 
with ExQW, which is yet to be evaluated in large numbers 
of subjects with type 2 diabetes.
Gliptins
The gliptins inhibit dipeptidyl peptidase-4 and increase levels 
of endogenous glucagon-like peptide-1 to augment glucose-
mediated insulin secretion. To date, ExQW has only been 
compared with one dipeptidyl peptidase-4 inhibitor, which 
was sitagliptin, and ExQW was shown to lower HbA
1c
 to 
a greater extent than sitagliptin. It has been suggested that 
vildagliptin is more potent than sitagliptin at reducing HbA
1c
 
in Japanese subjects with type 2 diabetes.54 Thus, it is pos-
sible that ExQW may not be more potent than gliptins other 
than sitagliptin. Thus, a direct comparison of ExQW and 
vildagliptin should be undertaken in subjects with type 2 
diabetes. Further, it is possible that the effects of ExQW and 
the gliptins are additive, with ExQW directly stimulating 
the receptor for glucagon-like peptide-1, and the gliptins 
causing a buildup of endogenous glucagon-like peptide-1, 
which also stimulates the receptor. This should be tested in 
subjects with poorly managed type 2 diabetes despite using 
either ExQW or a gliptin.
Comparison with sulfonylureas
When metformin is ineffective at controlling type 2 dia-
betes alone, the standard group of drugs added are the 
 sulfonylureas. Although effective at reducing HbA
1c
 in the 
presence of metformin, the sulfonylureas increase the inci-
dence of hypoglycemia. Thus, when type 2 diabetes is not 
controlled by metformin alone, ExQW should be trialed as 
an alternative to a sulfonylurea. Such a trial should compare 
not only the incidence of hypoglycemia between ExQW and 
a sulfonylurea, but also efficacy and other aspects of safety 
in subjects with type 2 diabetes being poorly managed with 
metformin.
Add-on to insulin
Adding ExBID to insulin glargine has been shown to be 
effective in the treatment of subjects with type 2 diabetes. 
Thus, addition of ExBID is associated with a lowering 
of HbA
1c
, lower basal insulin requirements, and with 
weight loss or less weight gain, as extensively reviewed 
 elsewhere.55 However, the effects of adding ExQW to 
insulin glargine have not been assessed in a clinical trial, 
and should be.
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Preference and adherence
There is limited information available for preference and 
adherence with ExQW. ExQW was preferred to ExBID 
in DURATION-1, as discussed earlier. However, it is not 
known whether ExQW is preferred to other diabetic medi-
cines, and this needs to be investigated.
Because it takes 3 weeks to drop from steady state 
to below therapeutic levels with ExQW,18 subjects with 
type 2 diabetes who miss the occasional dose of ExQW may 
maintain reasonable glycemic control, and this needs to be 
 investigated. Other antidiabetic medicines, including ExBID, 
have shorter durations of action than ExQW, and nonadher-
ence with these other diabetic medicines may be associated 
with poorer glycemic control than with ExQW. This com-
parison also needs to be undertaken. Very high adherence 
to ExQW has been reported in the clinical trial setting,20 but 
this needs to be assessed in practice. Higher adherence with 
ExBID than with insulin glargine has been reported,35 but 
comparison of adherence rates between ExQW and insulin 
glargine needs investigating.
Archimedes diabetes simulation  
and AHEAD trial
In the modeling of a GLP-1 agonist in diabetes, Peskin et al 
considered the agonist to be equivalent to glycemic control 
and weight reduction or these plus additional improvements 
in systolic blood pressure and lipids.51 This modeling sug-
gested that there would be improvements in cardiovascular 
outcomes associated with these changes.51 The Action for 
Health in Diabetes (Look AHEAD) trial was designed to 
determine whether intensive lifestyle changes compared with 
diabetes support and education would improve cardiovascular 
outcomes.56 In this trial, after 4 years, physical activity was 
greater, weight loss was about 5 kg, and HbA
1c
 was lowered 
by 0.5% in the lifestyle group.57 However, there was no evi-
dence of improved cardiovascular outcomes in the intensive 
lifestyle change group, compared with the diabetes support 
and education group, and the trial has been abandoned for 
futility.58
Given that Archimedes modeling of the GLP-1 agonist 
was based on it being equivalent to lifestyle changes,51 
similar results from the simulation and real trial might be 
expected, but this did not occur. One possible explana-
tion for this is that the modeling produced much larger 
decreases in body weight and HbA
1c
 than were observed 
in the Look AHEAD trial, and these larger decreases 
are needed to achieve an improvement in cardiovascular 
outcomes.
Conclusion
The clinical trials with ExBID established a role for 
exenatide in the treatment of type 2 diabetes. Subsequently, 
ExQW was shown to have advantages over ExBID, and 
there is now more emphasis on the development of ExQW. 
ExQW alone reduces HbA
1c
 and body weight, and is well 
tolerated. ExQW has been compared with sitagliptin, piogli-
tazone, and metformin, and shown to have a greater ability 
to reduce HbA
1c
 than these other medicines. ExQW has been 
compared with insulin glargine, and ExQW causes weight 
loss compared with a weight gain with insulin glargine. 
ExQW has been compared with another GLP-1 receptor 
agonist, liraglutide, and the results suggest that ExQW is 
noninferior to  liraglutide. The small amount of evidence 
available shows that subjects with type 2 diabetes prefer 
ExQW to ExBID, and that adherence was high in the clinical 
trial setting. Health care and economic modeling suggests 
that ExQW will reduce diabetic complications and be cost-
effective compared with other medications in long-term use. 
Little is known about whether subjects with type 2 diabetes 
prefer ExQW to other medicines and whether adherence 
with ExQW is good in practice, and these important topics 
require further study.
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